Worldwide Clinical Trials Drug Development Solutions (formerly CEDRA Clinical Research)
San Antonio, Texas, 78217, United States
NCT Number: NCT01703468
The objective of this study was to prove the bioequivalence of Roxane Laboratories' Oxcarbazepine Suspension 600 mg under fed conditions
Looking for future studies?
Notify Me18 year–45 year
All sexes
Interventional
Phase 1
San Antonio, Texas, 78217, United States
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Other names: Trileptal
Time frame: 10 days
Blood sampling taken during specified time points to determine bioequivalence
Roxane Laboratories
Industry
A Single Dose, Two-Period, Two-Treatment, Two-Sequence Crossover Bioequivalence Study of Oxcarbazepine 600 mg Suspension Under Fed Conditions
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06714448
Brain Diseases, Central Nervous System Diseases
Chilly-Mazarin, France
View Trial DetailsNCT04770337
Brain Diseases, Central Nervous System Diseases
Phoenix, Arizona, United States
View Trial DetailsNCT07257705
Clinical Decision Support Systems, Diarrhea Infectious
Kalongo, Agago District, Uganda
View Trial DetailsNCT04259125
Brain Diseases, Central Nervous System Diseases
Oakland, California, United States
View Trial Details